Rocket Doctor Partners with Melanoma Canada to Expand Access to Follow-Up Care for At-Risk Patients
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) announced that its virtual care subsidiary, Rocket Doctor, has partnered with Melanoma Canada to provide follow-up care for patients identified as at-risk during mobile skin cancer screenings. The partnership will facilitate direct referrals to Rocket Doctor physicians through a digital intake process for patients without family doctors across Ontario, Alberta, and British Columbia.
The collaboration involves Melanoma Canada's Mole Mobile units, which offer free skin cancer screenings in remote and urban communities. The initiative addresses a critical healthcare need, as skin cancer represents 1 in 3 cancer diagnoses in Canada, with 22 Canadians diagnosed with melanoma daily. The 12-month agreement, starting February 3, 2025, includes branding opportunities on Mole Mobile vans and campaign materials.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha annunciato che la sua controllata di assistenza virtuale, Rocket Doctor, ha stretto una partnership con Melanoma Canada per offrire cure di follow-up ai pazienti identificati come a rischio durante gli screening mobili per il cancro della pelle. La collaborazione permetterà di indirizzare direttamente i pazienti senza medico di famiglia nelle province di Ontario, Alberta e British Columbia ai medici di Rocket Doctor tramite un processo digitale di accettazione.
La partnership coinvolge le unità Mole Mobile di Melanoma Canada, che offrono screening gratuiti per il cancro della pelle in comunità remote e urbane. L’iniziativa risponde a un bisogno sanitario cruciale, dato che il cancro della pelle rappresenta 1 diagnosi su 3 in Canada, con 22 canadesi diagnosticati con melanoma ogni giorno. L’accordo, della durata di 12 mesi a partire dal 3 febbraio 2025, include opportunità di branding sui veicoli Mole Mobile e sui materiali della campagna.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) anunció que su subsidiaria de atención virtual, Rocket Doctor, se ha asociado con Melanoma Canada para brindar seguimiento a pacientes identificados como de riesgo durante los exámenes móviles de cáncer de piel. La alianza facilitará referencias directas a los médicos de Rocket Doctor mediante un proceso digital para pacientes sin médico de familia en Ontario, Alberta y Columbia Británica.
La colaboración involucra las unidades Mole Mobile de Melanoma Canada, que ofrecen exámenes gratuitos de cáncer de piel en comunidades remotas y urbanas. La iniciativa responde a una necesidad crítica de salud, ya que el cáncer de piel representa 1 de cada 3 diagnósticos de cáncer en Canadá, con 22 canadienses diagnosticados con melanoma diariamente. El acuerdo de 12 meses, que inicia el 3 de febrero de 2025, incluye oportunidades de marca en las camionetas Mole Mobile y materiales de campaña.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF)는 가상 진료 자회사인 Rocket Doctor가 Melanoma Canada와 협력하여 이동식 피부암 검사에서 위험군으로 분류된 환자들에게 후속 진료를 제공한다고 발표했습니다. 이 파트너십은 온타리오, 앨버타, 브리티시컬럼비아 지역에서 가정의가 없는 환자들을 위한 디지털 접수 과정을 통해 Rocket Doctor 의사에게 직접 의뢰할 수 있도록 지원합니다.
이 협력은 Melanoma Canada의 Mole Mobile 유닛과 함께 진행되며, 이 유닛은 외딴 지역과 도시 지역에서 무료 피부암 검진을 제공합니다. 이 이니셔티브는 캐나다에서 암 진단의 3분의 1을 차지하는 피부암 문제를 해결하는 중요한 의료 요구를 반영하며, 매일 22명의 캐나다인이 흑색종 진단을 받고 있습니다. 2025년 2월 3일부터 시작되는 12개월 계약에는 Mole Mobile 차량과 캠페인 자료에 브랜드 노출 기회가 포함됩니다.
Treatment.com AI Inc. (CSE : TRUE, OTC : TREIF) a annoncé que sa filiale de soins virtuels, Rocket Doctor, s’est associée à Melanoma Canada pour assurer le suivi des patients identifiés à risque lors des dépistages mobiles du cancer de la peau. Ce partenariat permettra des orientations directes vers les médecins de Rocket Doctor via un processus d’admission numérique pour les patients sans médecin de famille en Ontario, en Alberta et en Colombie-Britannique.
La collaboration implique les unités Mole Mobile de Melanoma Canada, qui offrent des dépistages gratuits du cancer de la peau dans les communautés rurales et urbaines. Cette initiative répond à un besoin crucial en santé, le cancer de la peau représentant 1 cas sur 3 de cancer au Canada, avec 22 Canadiens diagnostiqués avec un mélanome chaque jour. L’accord de 12 mois, débutant le 3 février 2025, inclut des opportunités de visibilité de marque sur les véhicules Mole Mobile et les supports de campagne.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) gab bekannt, dass seine virtuelle Pflege-Tochtergesellschaft Rocket Doctor eine Partnerschaft mit Melanoma Canada eingegangen ist, um Nachsorge für Patienten anzubieten, die bei mobilen Hautkrebsscreenings als gefährdet identifiziert wurden. Die Partnerschaft ermöglicht direkte Überweisungen zu Rocket Doctor-Ärzten über einen digitalen Aufnahmeprozess für Patienten ohne Hausarzt in Ontario, Alberta und British Columbia.
Die Zusammenarbeit umfasst die Mole Mobile-Einheiten von Melanoma Canada, die kostenlose Hautkrebsscreenings in abgelegenen und städtischen Gemeinden anbieten. Die Initiative adressiert einen kritischen Gesundheitsbedarf, da Hautkrebs 1 von 3 Krebsdiagnosen in Kanada ausmacht und täglich 22 Kanadier mit Melanom diagnostiziert werden. Die 12-monatige Vereinbarung, beginnend am 3. Februar 2025, beinhaltet Branding-Möglichkeiten auf Mole Mobile-Fahrzeugen und Kampagnenmaterialien.
- None.
- Limited geographical coverage (only Ontario, Alberta, and British Columbia)
- Seasonal operation (through October 2025) may impact consistent patient flow
New collaboration will connect patients flagged during mobile skin cancer screenings with Rocket Doctor physicians across Ontario, Alberta, and British Columbia
●Rocket Doctor has partnered with Melanoma Canada to provide timely follow-up care for patients identified as at-risk during mobile skin cancer screenings.
●Patients without a family doctor will be directly referred to physicians on Rocket Doctor through a streamlined digital intake process.
●The Mole Mobile campaign travels across Alberta, British Columbia, Ontario, and Quebec, providing free screenings in both remote and urban communities.
●Skin cancer is the most common cancer in Canada, with 1 in 3 cancer diagnoses being skin-related — more than breast, prostate, lung, and colon cancers combined.
●22 Canadians are diagnosed with melanoma every day, and 3 Canadians die daily from this serious form of skin cancer.
●The partnership is expected to increase patient visits on Rocket Doctor’s platform, improving access to care and continuity for at-risk individuals.
Toronto, ON, May 20, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is proud to announce that its virtual care subsidiary, Rocket Doctor Inc., has partnered with Melanoma Canada to help bridge the care gap for individuals identified as at-risk for melanoma and other skin cancers during mobile screening events across the country.
Melanoma Canada’s Mole Mobile units, Canada’s first mobile skin cancer screening clinics, presented by Neutrogena®, a Kenvue brand travel across Alberta, British Columbia, Ontario, and Quebec, offering free skin checks from certified dermatologists in both remote and urban communities. Through this partnership, Rocket Doctor will provide patients who do not have a family physician with timely access to follow-up appointments via its virtual care platform.
“Too many Canadians are going without the care they need simply because they don’t have a family doctor,” said Dr. William Cherniak, Founder and CEO of Rocket Doctor. “By partnering with Melanoma Canada, we’re making it easier for patients identified during these critical screenings to get connected to a physician quickly, ensuring no one falls through the cracks.”
Dermatologists working in the Mole Mobile units will complete an on-site risk assessment and referral form for patients who require follow-up. These forms can then be uploaded directly to Rocket Doctor’s intake system, enabling efficient, streamlined review and timely access to appropriate care.
The need for follow-up care has never been more urgent. Skin cancer is the most commonly diagnosed cancer in Canada, more prevalent than breast, prostate, lung, and colon cancers combined. One in every three cancers diagnosed in Canada is a skin cancer, and the incidence of melanoma, the deadliest form, continues to rise. Every day, 22 Canadians are diagnosed with melanoma, and 3 die from it.
“With one in three cancers diagnosed in Canada being skin cancer, access to timely follow-up care is crucial,” said Falyn Katz, CEO of Melanoma Canada. “Our partnership with Rocket Doctor ensures that individuals flagged during our screenings, many of whom don’t have a family doctor, can seamlessly transition from screening to care. It’s a powerful step forward in improving outcomes for patients who might otherwise be left waiting.”
The initiative is expected to increase patient traffic across Rocket Doctor’s platform during Mole Mobile’s national tour, while reinforcing Rocket Doctor’s mission to improve equitable access to physician-led care. As part of the collaboration, Rocket Doctor’s logo will also appear on Mole Mobile vans and campaign materials, which collectively generate millions of impressions throughout the tour. The term of this Agreement is 12 months commencing February 3, 2025, and will automatically renew for successive 12-month periods unless either party provides at least 30 days’ written notice of termination prior to the renewal date.
Initial events will kick off in Toronto and Edmonton this spring, with additional stops planned through October 2025.
About Rocket Doctor Inc.
Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like.
Visit www.rocketdoctor.ca or contact media@rocketdoctor.io.
About Melanoma Canada
Melanoma Canada is a national organization dedicated to raising awareness, advancing prevention, and supporting patients affected by melanoma and skin cancer. Through programs like the Mole Mobile, Canada’s first mobile skin cancer screening initiative, Melanoma Canada brings early detection, education, and hope to communities across the country. In partnership with Canadian dermatologists, the Mole Mobile has screened thousands of individuals and identified hundreds of potential skin cancers.
Learn more at www.melanomanetwork.ca.
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment.com AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. Treatment.com AI’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities.
Learn more at www.treatment.com or contact info@treatment.com.
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
Email: ehamza@treatment.com
Media inquiries: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statement
This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
FAQ
What is the partnership between Treatment.com's Rocket Doctor (TREIF) and Melanoma Canada?
How will the Rocket Doctor (TREIF) and Melanoma Canada partnership work?
What is the duration of the agreement between Treatment.com (TREIF) and Melanoma Canada?
What regions will the Rocket Doctor (TREIF) and Melanoma Canada partnership cover?
How significant is the skin cancer screening need that Treatment.com (TREIF) is addressing?
